肾细胞癌血清蛋白标志物的研究进展  

Research Progress in Serum Protein Markers of Renal Cell Carcinoma

作　　者：付玉麟 黄飚 周秀梅[1] FU Yulin;HUANG Biao;ZHOU Xiumei(College of Life Sciences and Medicine,Zhejiang Sci-Tech University,Hangzhou 310018,China)

机构地区：[1]浙江理工大学生命科学与医药学院,杭州310018

出　　处：《中国细胞生物学学报》2022年第10期2013-2020,共8页Chinese Journal of Cell Biology

摘　　要：肾细胞癌是泌尿系统最常见的恶性肿瘤。近年来,随着“靶向疗法”的开发与应用,肾细胞癌的治疗取得了很大进展,但靶向疗法主要针对的是晚期肾细胞癌或无法手术的肾细胞癌患者。早期肾细胞癌如果能得到及时的手术治疗其5年生存率可以达到90%以上,但晚期肾细胞癌的5年总体生存率却急剧下降,仅为12%。肾细胞癌起病隐匿无明显临床特征令患者不易察觉,临床上肾细胞癌的病例大多是因其他原因进行检查(即腹部成像)期间偶然发现的,往往被诊时已发展到晚期或是进展为远处转移,导致预后不良。目前已发现多种癌症血清蛋白标志物,且它们对肾细胞癌临床早期诊断显示出极好的效果。该文对近几年发现的肾细胞癌血清蛋白标志物进行了回顾性综述,以期为疾病的早期诊断、治疗、病程监控及预后评估提供理论参考。Renal cell carcinoma is the most common malignancy of the urinary system.In recent years,with the development and application of “targeted therapy”,the treatment of renal cell carcinoma has made great progress,but targeted therapy mainly targets patients with advanced renal cell carcinoma or inoperable renal cell carcinoma.The 5-year survival rate of early-stage renal cell carcinoma can reach more than 90% if timely operation,but the 5-year overall survival rate of advanced renal cell carcinoma drops sharply to only 12%.Renal cell carcinoma has hidden onset and no obvious clinical features,which makes it difficult for patients to detect it.Clinical cases of renal cell carcinoma are mostly discovered incidentally during tests (i.e.,abdominal imaging) performed for other reasons,and often have advanced stage or have progressed to distant metastasis at the time of diagnosis,leading to poor prognosis.A variety of cancer serum protein markers have been found,which show excellent effect on early clinical diagnosis of renal cell carcinoma.This article reviews the serum protein markers found in renal cell carcinoma in recent years,in order to provide theoretical reference for early diagnosis,treatment,course monitoring and prognosis assessment of the disease.

关 键 词：肾细胞癌 血清蛋白标志物 诊断 预后 临床 

分 类 号：R737.11[医药卫生—肿瘤]